Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced patent number 12,221,654 was issued on February 11, 2025, by the United ...

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...

The FDA has granted orphan drug designation (ODD) and RPDD to Arbor Biotechnologies' ABO-101, to treat primary hyperoxaluria ...

Adial Pharmaceuticals (ADIL) announced patent number 12,221,654 was issued on February 11, 2025, by the United States Patent and Trademark ...

Novo Nordisk announced plans for a longer phase III trial testing its investigational obesity drug CagriSema, with regulatory ...

GLEN ALLEN, Va. - Adial Pharmaceuticals, Inc. (NASDAQ:ADIL), a biopharmaceutical company specializing in addiction treatment with a current market capitalization of $5 million, has been granted a new ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug application ...

Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...

New Patent expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating ...

today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug application (IND) to initiate a clinical study of the company’s investigational UKidney ...

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced that the U.S. Food and Drug Administration ( FDA ) has cleared its Investigational N ...